{"nctId":"NCT00790192","briefTitle":"Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.","startDateStruct":{"date":"2008-10"},"conditions":["Schizophrenia"],"count":488,"armGroups":[{"label":"Lurasidone 80mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone"]},{"label":"Lurasidone 160mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone"]},{"label":"Quetiapine XR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Quetiapine XR"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Lurasidone","otherNames":[]},{"name":"Lurasidone","otherNames":[]},{"name":"Quetiapine XR","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provide written informed consent and aged between 18 and 75 years of age.\n* Meets DSM-IVâ„¢ criteria for a primary diagnosis of schizophrenia.\n* Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.\n* Able and agrees to remain off prior antipsychotic medication for the duration of study.\n* Good physical health on the basis of medical history, physical examination, and laboratory screening.\n* Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.\n\nExclusion Criteria:\n\n* Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.\n* Any chronic organic disease of the CNS (other than schizophrenia).\n* Used investigational compound within 30 days.\n* Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase","description":"The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.2","spread":null},{"groupId":"OG001","value":"-26.5","spread":null},{"groupId":"OG002","value":"-27.8","spread":null},{"groupId":"OG003","value":"-10.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment","description":"Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null},{"groupId":"OG001","value":"-1.7","spread":null},{"groupId":"OG002","value":"-1.7","spread":null},{"groupId":"OG003","value":"-0.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":125},"commonTop":["Headache","Insomnia","Dizziness","Somnolence","Vomiting"]}}}